Long-term shedding from fully convalesced individuals indicates that Pacific herring are a reservoir for viral hemorrhagic septicemia virus

被引:7
|
作者
Hershberger, P. K. [1 ]
MacKenzie, A. H. [1 ]
Gregg, J. L. [1 ]
Wilmot, M. D. [1 ]
Powers, R. L. [2 ]
Purcell, M. K. [2 ]
机构
[1] US Geol Survey, Western Fisheries Res Ctr, Marrowstone Marine Field Stn, Nordland, WA 98328 USA
[2] US Geol Survey, Western Fisheries Res Ctr, Seattle, WA 98115 USA
关键词
Pacific herring; VHSV-IVa; Shedding; Gills; Reservoir; RAINBOW-TROUT; GENOGROUP IVA; INFECTION; VHSV; HOST; PATHOLOGY; DISEASE; MARINE;
D O I
10.3354/dao03595
中图分类号
S9 [水产、渔业];
学科分类号
0908 ;
摘要
Processes that allow viral hemorrhagic septicemia (VHS) virus to persist in the marine environment remain enigmatic, owing largely to the presence of covert and cryptic infections in marine fishes during typical sub-epizootic periods. As such, marine host reservoirs for VHS virus have not been fully demonstrated, nor have the mechanism(s) by which infected hosts contribute to virus perpetuation and transmission. Here, we demonstrate that after surviving VHS, convalesced Pacific herring continue to shed virus at a low rate for extended periods. Further, exposure of previously naive conspecific sentinels to this shed virus can result in infections for at least 6 mo after cessation of overt disease. This transmission mechanism was not necessarily dependent on the magnitude of the disease outbreak, as prolonged transmission occurred from 2 groups of donor herring that experienced cumulative mortalities of 4 and 29%. The results further suggest that the virus persists in association with the gills of fully recovered individuals, and long-term viral shedding or shedding relapses are related to cooler or decreasing water temperatures. These results provide support for a new VHS virus perpetuation paradigm in the marine environment, whereby the virus can be maintained in convalesced survivors and trafficked from these carriers to sympatric susceptible individuals.
引用
收藏
页码:245 / 252
页数:8
相关论文
共 35 条
  • [31] Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study
    Katlama, Christine
    Assoumou, Lambert
    Valantin, Marc-Antoine
    Soulie, Cathia
    Martinez, Esteban
    Beniguel, Lydie
    Bouchaud, Olivier
    Raffi, Francois
    Molina, Jean-Michel
    Fellahi, Soraya
    Peytavin, Gilles
    Marcelin, Anne-Genevieve
    Kolta, Sami
    Capeau, Jacqueline
    Gibowski, Severine
    Cardon, Fanny
    Reynes, Jacques
    Costagliola, Dominique
    Bernard, Louis
    Bottero, Julie
    Bouchaud, Olivier
    Chidiac, Christian
    Duvivier, Claudine
    Goujard, Cecile
    del Mar Gutierrez, Maria
    Martinez, Esteban
    Molina, Jean-Michel
    Morlat, Philippe
    Naqvi, Alissa
    Podzamczer, Daniel
    Poizot-Martin, Isabelle
    Raffi, Francois
    Reynes, Jacques
    Salmon-Ceron, Dominique
    Simon, Anne
    Valantin, Marc-Antoine
    Weiss, Laurence
    Yazdanpanah, Yazdan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (09) : 2742 - 2751
  • [32] Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study
    Del Puente, Filippo
    Berruti, Marco
    Riccardi, Niccolo
    Di Biagio, Antonio
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) : 3698 - 3699
  • [33] Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-Infected individuals receiving long-term highly active antiretroviral therapy
    Chun, TW
    Justement, JS
    Pandya, P
    Hallahan, CW
    McLaughlin, M
    Liu, SY
    Ehler, LA
    Kovacs, C
    Fauci, AS
    JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (11): : 1672 - 1676
  • [34] Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response
    Katlama, Christine
    Assoumou, Lambert
    Valantin, Marc-Antoine
    Soulie, Cathia
    Martinez, Esteban
    Beniguel, Lydie
    Bouchaud, Olivier
    Raffi, Francois
    Molina, Jean-Michel
    Fellahi, Soraya
    Peytavin, Gilles
    Marcelin, Anne-Genevieve
    Kolta, Sami
    Capeau, Jacqueline
    Gibowski, Severine
    Cardon, Fanny
    Reynes, Jacques
    Costagliola, Dominique
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) : 3699 - 3700
  • [35] Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)
    Wyles, David L.
    Kang, Minhee
    Matining, Roy M.
    Murphy, Robert L.
    Peters, Marion G.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (12):